ABSTRACT
INTRODUCTION
AR is a nuclear transcription factor that executes key function in normal and malignant growth of the prostate gland [1] [2] [3] [4] [5] . The tight control of AR signaling is critical in maintaining the homeostasis of the prostate gland. Malignancy of prostate still remains the most common cancer detected in American men and second leading cause of cancer related deaths [6, 7] . Cancerassociated dysfunctions of AR, such as aberrant activation due to mutations, amplification, splicing and cross talk with other pro-cancer signaling pathways contribute to prostate cancer (CaP) development and progression [1] [2] [3] [4] [5] 8] . In clinical practice, androgen ablation continues to be the corner stone for the treatment of advanced CaP [7, [9] [10] [11] . Unfortunately, androgen ablation treated CaPs eventually become treatment resistant, the stage of the disease known as castration resistant CaP (CRPC). Altered AR expression or function (gain or loss) resulting from genomic or non-genomic mechanisms associate with CRPC [1] [2] [3] [4] [5] . In contrast to other aspects of AR alterations, only a few studies have addressed how AR protein turnover is altered in CaP [12, 13] . A shorter half-life of AR was noted in the androgen responsive LNCaP cells as compared to its longer half life in the androgen refractory derivative C4-2B cells [14] . Early reports of the mechanisms of AR degradation showed that MDM2 E3 ubiquitin ligase targeted the AR through AKT mediated phosphorylation of MDM2 [15] . Our studies have implicated NEDD4 E3 ligase in AR degradation [16] [17] [18] [19] . Studies have also described downregulation of AR by proteasome dependent degradation during mitosis suggesting AR as a licensing factor for DNA replication in CaP cells [20, 21] . Emerging data also suggests for the role of other E3 ubiquitin ligases (CHIP, SKP2, Siah2, RNF6) in the AR degradation or transcriptional activation [13] . A recent report showed that SPOP E3 ubiquitin ligase degrades AR protein and the recurrent genomic mutations of the SPOP noted in 5-10% of CaPs impair the SPOP mediated AR degradation [22, 23] .
PMEPA1 was originally identified by our laboratory as a prostate abundant, highly androgen induced gene that mapped to chromosome 20q13.31-q13.33 [16] . Human PMEPA1 protein exhibits 83% amino acid identity to the mouse Nedd4-bindng protein, N4wbp4 [16, 24] . PMEPA1 is a direct transcriptional target of AR in CaP cells [18] . Further Investigations discovered a PMEPA1-AR negative feedback loop in the regulation of AR protein levels in CaP cells [19] . Members of the NEDD4 family of proteins are E3 ubiquitin ligases, which catalyze degradation of target proteins of physiologically important functions by the ubiquitinprosteasome pathway [25, 26] . Initial evaluations of PMEPA1 mRNA expression in matched normal and prostate tumor specimens suggested decreased expression of PMEPA1 in two-third of CaP patients [17] . In contrast to CaPs, higher expression of PMEPA1 has been noted in multiple solid tumors [27, 28] . Studies have also shown induction of PMEPA1 expression by transforming growth factor-β (TGF-β) that was associated with colonocyte terminal differentiation [29] . Subsequent studies have defined that PMEPA1 inhibits TGF-β receptor 1 meditated signaling through a negative feedback loop by sequestering R-Smads [30] . Increased PMEPA1 expression in breast and lung cancer may lead to inhibition of TGF-β signaling [31] [32] [33] . PMEPA1 has also been reported to promote the proliferation of AR negative CaP cells, PC3, through the Smad3-4/C-MYC/p21Cip1 pathway [34, 35] . Taken together, both reduced and increased PMEPA1 expression may promote tumorigenesis through distinct cell signaling pathways in a given cellular background.
In this report, we present new findings on the cancer biologic properties of decreased PMEPA1 expression. Loss or decreased PMEPA1 expression in CaP contributes to accelerated cell growth through increased AR and NEDD4, decreased PTEN levels and confers resistance to AR inhibitors used in androgen ablation therapy.
RESULTS

Inhibition of PMEPA1 promotes the growth of prostate cancer cells
We have examined the impact of PMEPA1 depletion on tumor growth in vivo. We have characterized PMEPA1shRNA-LNCaP and PMEPA1shRNA-VCaP stable transfectants to assess the growth of prostate tumor cells in vitro. We observed enhanced cancer cell biologic features by monitoring cell growth, BrdU incorporation, cell plating efficiency, soft agar colony formation, growth response to androgen and cell cycle (Supplementary Figure 1) .
We evaluated the tumor growth characteristics of PMEPA1shRNA harboring LNCaP cells in athymic nude mouse tumor xenograft model. The PMEPA1shRNA-LNCaP and control shRNA-LNCaP cells began to form subcutaneous tumors at 4 weeks post-injection. The overall growth of PMEPA1shRNA-LNCaP derived tumors was significantly faster than control derived tumors (p < 0.05) ( Figure 1A ). At 9 week post-injection among 20 mice in each group, 18 mice formed measurable subcutaneous tumors in the PMEPA1shRNA-LNCaP group. In contrast, only 12 mice formed tumors in the control group. The tumor formation rate was 90% in the PMEPA1shRNA-LNCaP group and only 60% in the control. The average tumor volume was 2246.04 mm 3 for PMEPA1shRNA-LNCaP and 1211.64 mm 3 for the control. PMEPA1shRNA-LNCaP tumors expressed higher levels of AR and PSA proteins compared to control cells as assessed by immunohistochemistry (IHC) ( Figure 1B and Table 1 ). The tumor size in the control group decreased 21% at two weeks post-injection in response to castration. In contrast, PMEPA1shRNA-LNCaP xenografts were refractory to castration. By seven weeks post-castration, the overall tumor size was four times larger than the initial tumor size (100%) in PMEPA1shRNA harboring xenografts (increased by 304%), in contrast to the control group (increased by 69%) (p < 0.05) ( Figure 1C ). Taken together, both in vitro and in vivo growth characteristics of PMEPA1shRNA harboring cells resulted in increased AR, gain of AR function and accelerated tumor growth under normal, as well as under castrate conditions.
PMEPA1 depletion leads to resistance to AR inhibitors
To further investigate the role of decreased PMEPA1 levels in enhancing tumor cell growth by gain of AR function, dose and time kinetic response to the AR inhibitors, enzalutamide and bicalutamide were assessed in cell growth assays. PMEPA1 depletion conferred resistance to AR inhibitors in both LNCaP and VCaP cells (Figure 2A and 2B, Supplementary Figure 2A and 2B). Additionally, enhanced resistance to AR inhibitors was confirmed by BrdU incorporation, soft agar colony formation and www.impactjournals.com/oncotarget Figure  2C -2E). Consistent with these observations, cell cycle analysis showed higher number of cells in S-phase and decreased rate of apoptosis in response to PMEPA1 inhibition (Table 2 and Supplementary Figure 2F ). The observed enhanced resistance to AR inhibitors in response to PMEPA1 depletion was consistent with the observed castration resistance of PMEPA1shRNA harboring tumor xenografts. Taken together, these data suggest that loss or decreased PMEPA1 levels confers resistance to AR inhibitors.
PMEPA1 silencing rescues AR inhibition in prostate cancer cells
In hormone sensitive CaP cells, decreased AR expression levels results in reduced cell growth. However, under this condition, loss of PMEPA1 may supersede the growth effect of AR inhibition by stabilizing AR at protein levels. Thus, we evaluated if inhibition of PMEPA1 can restore CaP cell growth overriding the inhibition of AR. Indeed, co-transfection of AR and PMEPA1 siRNAs in LNCaP cells reversed effects of AR depletion by siRNA on AR protein ( Figure 3A ). While parental LNCaP cells exhibited severe growth inhibition in response to AR siRNA, simultaneous knockdown of PMEPA1 rescued the growth of cancer cells ( Figure 3B ). These data further supported that the observed enhanced cell proliferation in response to PMEPA1 depletion was due to elevated AR protein levels and AR signaling.
Disruption of AR and NEDD4 link by loss of PMEPA1
It was intriguing to note simultaneous increase of NEDD4 and AR in response to PMEPA1 knockdown ( Figure 4A ). This observation suggested that inhibition of PMEPA1 may disrupt interaction between NEDD4 Figure 4B ). Further, decreases in AR levels in response to ectopic PMEPA1 expression were abolished by NEDD4 knockdown in LNCaP cells ( Figure 4C ). As expected, the cell growth read out reflected the AR status ( Figure 4B and 4C). Conversely, ectopic expression of NEDD4 in PMEPA1 shRNA stable transfectants was refractory to AR biochemical signals and associated features ( Figure 4D ). These findings established that both PMEPA1 and NEDD4 are essential in AR mediated cell growth.
NEDD4 down-regulates AR protein levels and inhibits cell growth in hormone responsive prostate cancer cells
Our previous study has revealed that PMEPA1 binds to NEDD4 through the interaction between PY motifs of PMEPA1 and WW domain of human NEDD4 protein [17] . Thus, we evaluated the role of NEDD4 on CaP cell growth and AR protein levels. Knockdown of NEDD4 by specific siRNA led to strikingly elevated levels of AR and PSA in LNCaP and VCaP cells ( Figure 5A ). Conversely, ectopic expression of the NEDD4 resulted in decreased levels of AR protein in both LNCaP and VCaP cells ( Figure 5B ). Further, ectopic expression of NEDD4 resulted in a significant inhibition of cell growth ( Figure 5C and 5D ). In parallel, we also evaluated the effects MDM2 E3 ligase on AR which has been reported to be involved in AR degradation [15] . As expected, transfection of the MDM2 siRNA, resulted in elevated AR and PSA protein levels in both LNCaP and VCaP cells ( Figure 5E and 5F). Taken together, these findings underscored that NEDD4 mediates AR degradation and cell growth inhibition in hormone responsive VCaP and LNCaP cells.
NEDD4 facilitates PTEN degradation in PMEPA1 depleted cells
Genomic deletions and reduced expression of PTEN is frequently noted in CaPs which correlates with adverse pathologic features [36] . Ubiquitin-mediated degradation of PTEN by NEDD4 has been reported [37, 38] . As noted, above PMEPA1 depletion in CaP cells also resulted in elevated NEDD4 levels. Thus, we reasoned that decreased PMEPA1 may contribute to reduced levels of PTEN, a known NEDD4 target in CaP cells. In VCaP cells harboring wild type PTEN, ectopic expression of NEDD4 downregulates PTEN protein levels ( Figure 6A) . Moreover, the PMEPA1 knockdown led to elevated levels of AR protein, increased NEDD4 and decreased PTEN protein levels ( Figure 6B ). These findings suggest that loss of PMEPA1 may contribute to the defects of PTEN and alterations in NEDD4 through AR that is consistent with reported associations of PTEN and AR with CaP progression [36] . Thus, PMEPA1 may in part also affects NEDD4 mediated PTEN degradation in the context of androgen responsive CaP cells. However, NEDD4 can target PTEN independent of AR or PMEPA1. Ectopically expressed PTEN directly interacting with AR, has been shown to facilitate AR degradation and to inhibit AR nuclear translocation in PTEN null LNCaP cells [39] . Due to this reciprocal relationship between AR and PTEN, we evaluated the cooperative effects of PTEN knockdown and PMEPA1 depletion on cell growth, AR levels and AR transcriptional targets. Transfection of VCaP cells with PMEPA1 or PTEN siRNA resulted in enhanced cell growth, increased levels of AR and its targets, PSA and NEDD4. Cells depleted in both PMEPA1 and PTEN led to further increases in AR and cell growth ( Figure 6C and 6D) . Cumulatively, loss or reduced expression of PMEPA1 may lead to higher levels of AR and decreased levels of PTEN resulting in a feedforward enhancement in cell growth as shown in simultaneous depletion of PMEPA1 and PTEN. Higher ratio of PSA to PMEPA1 expression as a surrogate for increased AR function associates with more aggressive prostate cancer cells
The frequently observed silencing of PMEPA1 in CaP may result in stabilization of AR, leading to higher levels of AR and increased AR transcription factor activity. To assess this finding in human CaP specimens, laser capture micro-dissected matched benign and cancer epithelium derived RNA samples were evaluated for quantitative expression of PMEPA1 and PSA/KLK3 mRNA, a surrogate for AR transcriptional activation function, in frozen radical prostatectomy derived specimens from 82 patients. The experiment revealed a correlation of decreased PMEPA1 mRNA expression with increased PSA/KLK3 expression levels. The ratio of PSA and PMEPA1 T/N expression values in each patient was correlated with clinico-pathological characteristics. Higher PSA/PMEPA1 expression ratio significantly associated with multiple indicators of disease progression (tumor differentiation, (Table 3) . Thus, increased AR function as reflected by increased PSA/KLK3 expression along with reduced PMEPA1 expression associate with progressive CaP.
DISCUSSION
It is well recognized that the alterations (gain or loss) of the AR mediated signaling, play critical roles in the development and progression of CaP. While AR has been extensively studied for alterations of its structure, expression and transcriptional functions in CaP, defects of the AR protein degradation in CaP warrant careful evaluations. Better understanding of mechanisms controlling AR protein levels may also help in developing new therapeutic strategies focusing on AR degradation in a majority of metastatic CaP associating with the gain of AR function.
Cumulative data underscore the association of reduced or absent PMEPA1 expression in CaP cells with increased AR due to impaired AR degradation [17] [18] [19] . However, the impact of attenuated PMEPA1 expression in the interface of NEDD4, AR and PTEN in CaP biology and the effects on therapeutic AR inhibitors has not been examined before. Three major consequences of loss of PMEPA1 in CaP are summarized in the working model ( Figure 6E ). First, PMEPA1 knockdown accelerated the growth of LNCaP tumors in athymic nude mouse and in cell culture models. Second, PMEPA1 knockdown resulted in enhanced resistance to both enzalutamide and bicalutamide inhibitors of AR. Third, we noted that PMEPA1 silencing increased NEDD4-mediated downregulation of PTEN, further enhancing the growth of CaP cells. In agreement with cell culture models, in human CaP specimens decreased PMEPA1 expression correlated with increased AR transcriptional function as measured by PSA/KLK3 mRNA expression.
One of the new findings of this study is the androgen induction of NEDD4 E3 ligase that may impose additional level of hormonal control on AR and PTEN degradation (Supplementary Figure 3A-3C ). Previous studies reported androgen induction of NEDD4L transcripts [40] . Informatics analysis of regulatory elements in the NEDD4 gene locus indicated the presence of a cluster of androgen responsive elements (Supplementary Figure 3D) .
Of note, this study also provides novel findings of cooperation between PMEPA1 and PTEN defects leading to enhanced CaP cell growth. While PMEPA1 depletion uncouples NEDD4 from AR degradation, increased levels of NEDD4 remains available for PTEN degradation, leading to simultaneous gain of AR and loss of PTEN in CaP cells. Evaluating the mechanism of PMEPA1 silencing in previous studies we have shown that methylation of the first intronic DNA region of PMEPA1 gene is a prevalent mechanism of PMEPA1 silencing in human prostate CaP [41] . In conclusion, this study highlights that silencing of PMEPA1 accelerates the growth of CaP cells through AR, NEDD4 and PTEN. Taken together, these data provide support for the dual impact of PMEPA1 restoration as a complementary approach in correcting for AR and PTEN defects in CaP and highlights biomarker potential of monitoring PMEPA1 during androgen ablation therapy.
MATERIALS AND METHODS
Cell culture and related reagents
LNCaP and VCaP cells (from ATCC, Manassas VA) were maintained in RPMI 1640 and DMEM growth medium, respectively, supplemented with 10% fetal bovine serum (FBS). For the androgen-depletion experiments, cells were grown in 10% charcoal stripped FBS supplemented cell growth medium for 5 days. Subsequently, cells were treated with various dosages (0 nM, 0.1 nM, 1.0 nM and 10.0 nM) of synthetic androgen R1881 (Cat#NLP005005MG, Perkin Elmer Life Science, Waltham, MA) for indicated time. Hexamethrine bromide (Cat#H9268-5G) and puromycin (Cat#A1113802) used for selection PMEPA1 shRNA lentivirus transfectants were purchased from Sigma-Aldrich (St. Louis, MO).
Plasmids, small interfering (si) RNAs and shRNA lentiviruses
The mammalian plasmids used were as follows: pcDNA3.1 as vehicle control, pcDNA3.1-PMEPA1, pCMV-AR (wild-type) and pCMV-AR (mutant T877A) were described before (15, 37); pCMV-XL4 (vehicle control, Cat#PCMV6XL4) and pCMV-XL4-NEDD4 (Cat#SC107811) were purchased from OriGene (Rockville, MD). The siRNAs for various genes were all purchased from Dharmacon (Lafayette, CO). Each gene of interest was targeted with two different siRNAs (Supplementary 4A-4C) using optimal concentrations that were determined in pilot assays: PMEPA1 siRNA1: GTTATCACCACGTATATA; 
Cell counting assays
The CaP cells (LNCaP and VCaP cells) were seeded in 6 cm culture dishes at the density of 2 × 10 5 cells/dish. Cells were grown at 37°C, 5% CO 2 for 2 days followed by transfection with plasmids (pcDNA3.1, pcDNA3.1-PMEPA1, pCMV-XL4, pCMV-XL4-NEDD4 or pCMV-XL4-AR) or siRNA (non-targeting, PMEPA1, AR, NEDD4 or PTEN siRNA) using lipofectamine 2000 procedure. The AR inhibitors treatment experiments were conducted with PMEPA1 shRNA1 harboring LNCaP and VCaP cells. The transfected cells or the stable transfectants were harvested at indicated time points post-transfection with 0.25% trypsin plus EDTA (Life Technology, Carlsbad, CA). Cells were re-suspended into 10 ml regular medium, and 10 μl of single cell suspension was applied to hemocytometer for cell counting with trypan blue (Cat#72-57-1, SigmaAldrich, St. Louis, MO).
Cell cycle analysis by fluorescence activated cell sorting
Ten million cells of PMEPA1 shRNA transfectant LNCaP or VCaP cells were harvested by centrifugation at 180 × g for 5 min. Cells were resuspended in 300 μl PBS (pH 7.4), and 5 ml methanol was added drop-wise and vortexed at low speed. The fixed cells were incubated in methanol at -20°C for 30 min. After removing the methanol cells were stained by propidium iodide dye (Sigma-Aldrich, St. Louis, MO) at final concentration of 60 μg/ml containing 50 μg/ml RNaseA in PBS at room temperature (RT) for 30 min and were processed for fluorescence-activated cell sorting (FACS) analysis.
Western blot analysis
The cells were harvested with M-PER mammalian protein extraction reagent (Cat#78501, Thermo Scientific, Rockford, IL) supplemented with protease inhibitor mixture (Cat#P8340, Roche Applied Science, Indianapolis, IN) and phosphatase inhibitor mixture (Cat#P-0044, Sigma-Aldrich, St. Louis, MO). Cell lysates were analyzed using Western blot procedures described in details in the Supplementary Methods. 
Antibodies
Quantitative RT-PCR
Quantitative RT-PCR was performed using RNA laser capture microdissected matched normal and prostate tumor specimens as described in Sterbis et al [42] . PCR primers and Taqman probes were as follows: PMEPA1, 5′-CATGATCCCCGAGCTGCT-3′ (forward), 5′-TGATCTGAACAAACTCCAGCTCC-3′
(reverse), and 6FAM-5′-AGGCGGACAGTCTCCTGCGAAACC-3′-TAMRA (probe); PSA/KLK3, 5′-CCCACTG CATCAGGAACAAA-3′ (forward), 5′-GAGCGGGTGTG GGAAGCT-3′ (reverse), and 6FAM-5′-ACACAGGCCAG GTATTTCAGGTCAGCC-3′-TAMRA (probe). The expression of GAPDH served as an endogenous control measured in the same tube as the target gene (GAPDH control mix, Applied Biosystems). Target gene expression in each sample was normalized to GAPDH. Results were plotted as average Ct (cycle threshold) values of duplicate samples. Relative gene expression level was presented as dCt in tumor versus matched benign cells, where dCt represents normalized Ct value of target genes to GAPDH. Statistical analysis of quantitative expression of PMEPA1 and PSA mRNA was evaluated in 82 patients (164 tumor and matched normal samples). The sample size (N = 82) was determined by statistical power calculation (90% power with 0.05 alpha, two sided Chi-square test). Distributions of other clinico-pathological variables were examined by using Chi-square or Fisher exact tests.
Statistical analysis
If not otherwise stated, significant was calculated utilizing an unpaired t-test. Data are calculated as mean ±SEM or +SEM.
